SS-31 was synthesised by Peter Schiller and Hazel Szeto — hence "Szeto-Schiller 31" — initially as part of a broader programme investigating aromatic-cationic peptides and their unusual ability to cross cell membranes without needing a carrier. What Szeto's team discovered, almost unexpectedly, was that the peptide didn't just cross cell membranes: it concentrated at the inner mitochondrial membrane at levels more than 1,000 times higher than the surrounding cell.
The reason for this selective accumulation is elegant chemistry. SS-31 carries two positively charged amino acids — D-arginine and lysine — which are electrostatically attracted to the highly negatively charged cardiolipin molecules embedded in the inner mitochondrial membrane. At the same time, aromatic amino acids in its structure (phenylalanine and dimethyltyrosine) shield those charges just enough to maintain cell permeability. The result is a peptide that finds its target with unusual precision.
Development was taken forward by Stealth BioTherapeutics, which pursued clinical trials under the name elamipretide and later Bendavia. In September 2025, the FDA granted accelerated approval for elamipretide (brand name Forzinity) for the treatment of Barth syndrome — making it the first approved mitochondria-targeted therapy in the United States. This milestone transformed SS-31 from a compelling research compound into a drug with real clinical standing.
To understand SS-31, you first need to understand cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is not passive structural material. It is the scaffolding on which the electron transport chain is built. It holds the respiratory complexes in their correct shape and orientation, enabling efficient transfer of electrons and, ultimately, the production of ATP — the molecule your cells use for energy.
When cardiolipin becomes oxidised — by ageing, disease, or chronic metabolic stress — the scaffolding warps. The respiratory complexes become less efficient, electron leakage increases, reactive oxygen species (ROS) multiply, and ATP production falters. This is mitochondrial dysfunction, and it sits upstream of an extraordinary range of conditions: heart failure, neurodegeneration, muscle wasting, kidney disease, and the broader process of biological ageing.
What makes SS-31 scientifically interesting is that it does not simply mop up free radicals — a blunt mechanism used by many antioxidant supplements with limited clinical results. Instead, it acts upstream: by stabilising the architecture that generates ROS in the first place, it addresses the root cause rather than the downstream symptom. Researchers describe this as a structural intervention rather than a scavenging one.
SS-31 occupies an interesting place in the biohacking world. Unlike more accessible peptides such as BPC-157 or TB-500, it is harder to source, typically more expensive, and requires subcutaneous injection — factors that have kept it within a smaller, more technically-engaged subset of the community. Those who do use it tend to come with prior knowledge of mitochondrial biology and are often tracking biomarkers alongside their self-experimentation.
Community dosing protocols vary considerably. Some individuals use doses as low as 1–5mg subcutaneously several times per week, reasoning that the clinical trial doses (up to 40mg/day in some protocols) were designed for serious disease states and that meaningful mitochondrial effects might occur at lower doses in healthy individuals. This assumption has not been validated in any controlled study, and translating disease-state dosing to healthy-person optimisation remains one of the genuinely open questions in this space.
The FDA approval for Barth syndrome — and the human trial data behind it — has raised the community's confidence significantly. As one writer put it: "SS-31 is no longer just mouse magic. We have real human evidence now." That said, the gap between a genetic mitochondrial disease and general wellness optimisation is substantial, and the community's more thoughtful voices consistently acknowledge it.
The following benefit areas reflect findings from preclinical models, human clinical trials, and expanded-access case studies. Evidence strength is rated honestly — a distinction this book maintains throughout.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
SS-31 is, by the standards of the peptide world, unusually well-supported. It has a clearly understood mechanism, a substantial body of animal research, multiple completed human clinical trials, and as of September 2025, an FDA-approved indication. That is a combination most peptides discussed in wellness communities cannot match.
The fair question is: does the evidence for serious mitochondrial disease translate to meaningful benefit in healthy people seeking optimisation? The honest answer is that we don't know. The biological logic is coherent — mitochondrial function declines with age in everyone, not just those with genetic disorders — but logic is not data. No randomised controlled trial has examined SS-31 in healthy, non-diseased humans for longevity or performance purposes.
What we can say is that the safety profile from clinical trials is reassuring, the mechanism is genuinely novel, and the compound has now graduated from pure research curiosity to approved medicine. For a book about peptides and honesty, that deserves acknowledgment. For those considering self-experimentation: this is one of the more scientifically credible options in the mitochondrial category — and one where the risks, while real, appear manageable under careful conditions. Proceed with knowledge, not hype.